Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shandong Xinhua Pharmaceutical’s subsidiary, Xincat Pharmaceutical, has received approval from the National Medical Products Administration for its Azithromycin Suspension after passing the Generic Drugs Consistency Evaluation. This achievement marks a significant milestone in enhancing the company’s market presence and expanding its portfolio in the pharmaceutical industry.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.